Leveraging elite immune responses to develop novel cancer immunotherapies that expand the promise of immunotherapy



Making advancements in immuno-oncology through collaborators and strategic partnerships



Attractive preclinical pipeline of monoclonal antibodies focused on removing the brakes on immune cells in the tumor microenvironment

Our Mission

Attack cancer based on clues offered by the immune systems of Elite Cancer Responders

We are making cold tumors hot

OncoResponse utilizes a clinically validated Technology Platform to discover authentic human antibodies to multiple high value targets associated with immunosuppressive myeloid biology. We leverage the power of the Elite Responder’s immune system to discover immunomodulatory antibodies from patients who achieve exceptional responses to CPI therapies.


Our pipeline of antibodies is expected to relieve immunosuppression of the TME and augment immune activity to make “cold” tumors “hot”.